Karus is an emerging pharmaceutical company whose R&D activities are focused on the design and development of innovative, molecular-targeted, small molecule drugs to treat immune/inflammatory disorders and cancer.
In immune/inflammation, Karus's focus is centred on the design and development of a first generation of orally-active drugs that regulate Th17 cell function through the selective inhibition of PI3K-p110δ and HDAC6. These programmes bring the promise of innovative treatments for a broad spectrum of immune/inflammatory diseases, including rheumatoid arthritis, psoriasis, multiple sclerosis, airway inflammation and organ transplant rejection.
In cancer, Karus's research and development activities are focused on the development of selective inhibitors of PI3K-p110δ and p110β, and of key members of the zinc-dependent HDAC superfamily. Karus's cancer programmes promise innovative treatments for a broad range of haematological cancers and major solid tumours.
Karus is built on the scientific and commercial expertise of the company's executive management and board, who have established track-records of success in the biotechnology and pharmaceutical industries.
Despite advances in our understanding of the underlying mechanisms of human disease, there remain significant unmet medical needs, no more so than in the treatment of chronic immune diseases and cancer. Karus is addressing this challenge by applying its expertise in drug design, medicinal chemistry and target biology to create innovative drugs with significant clinical and commercial potential.
Simon Kerry, Chief Executive Officer
Karus Therapeutics Ltd
2 Venture Road
Southampton Science Park
Chilworth
Hampshire
SO16 7NP
United Kingdom